The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis

被引:0
作者
Ateefa Chaudhury
Asha Balakrishnan
Christy Thai
Bjorn Holmstrom
Sowmya Nanjappa
Zhenjun Ma
Michael V. Jaglal
机构
[1] H. Lee Moffitt Cancer Center & Research Institute,Department of Malignant Hematology
[2] University of South Florida,Department of Internal Medicine, Division of Hematology and Medical Oncology
[3] University of South Florida,Department of Internal Medicine
[4] H. Lee Moffitt Cancer Center & Research Institute,Department of Pharmacy
[5] H. Lee Moffitt Cancer Center & Research Institute,Department of Internal Hospital Medicine
[6] H. Lee Moffitt Cancer Center & Research Institute,Department of Biostatistics and Bioinformatics
来源
Indian Journal of Hematology and Blood Transfusion | 2018年 / 34卷
关键词
Venous thrombosis; Cancer associated thrombosis; Venous thromboembolism; Thrombosis; Novel anticoagulants;
D O I
暂无
中图分类号
学科分类号
摘要
Venous thromboembolism (VTE) is a complication of malignancy that is associated with significant mortality. The CLOT trial showed superiority of dalteparin in comparison to warfarin in preventing VTE recurrence. Rivaroxaban has been approved for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE). In the absence of large randomized trials in the oncology population, the efficacy and safety of rivaroxaban for the treatment of VTE in cancer patients needs to be assessed. A single-center retrospective chart review was conducted to assess the efficacy and safety of rivaroxaban compared with dalteparin in cancer-associated thrombosis. Out of 671 patients identified, 286 patients (107 in the rivaroxaban group and 179 in the dalteparin group) were eligible for analysis. The rivaroxaban group had a rate of VTE recurrence at 6 months of 4.9 versus 11.1% with dalteparin (p = 0.252). The incidence of recurrent DVT at 6 months was lower in patients treated with rivaroxaban (0%) compared with dalteparin (8.2%) at 6 months (p = 0.025). Incidence of recurrent PE in the rivaroxaban group (5%) versus dalteparin group (3.1%) at 6 months was not statistically significant (p = 0.675). No significant difference was identified between the rivaroxaban group and dalteparin group in the rate of major bleeding (2.8 vs. 1.1%, respectively). Rivaroxaban was comparable to dalteparin in prevention of VTE recurrence while having no significant differences with major or minor bleeding.
引用
收藏
页码:530 / 534
页数:4
相关论文
共 37 条
[1]  
White RH(2003)The epidemiology of venous thromboembolism Circulation 107 I-4-I-8
[2]  
Lyman GH(2015)Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 J Clin Oncol 33 654-656
[3]  
Bohlke K(2003)Venous thromboembolism and cancer: risks and outcomes Circulation 107 I-17-I-21
[4]  
Khorana AA(2010)Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy Thromb Haemost 104 1049-68
[5]  
Lee AY(2006)Incidence of venous thromboembolism in patients hospitalized with cancer Am J Med 119 60-1072
[6]  
Levine MN(2006)Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 1062-153
[7]  
Di Nisio M(2003)Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 146-1297
[8]  
Ferrante N(2012)Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 2012 1287-2510
[9]  
De Tursi M(2010)Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 2010 2499-694
[10]  
Stein PD(2005)Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 692-e46